Vemurafenib Interactions
There are 626 drugs known to interact with vemurafenib, along with 7 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 230 are major, 375 are moderate, and 21 are minor.
- View all 626 medications that may interact with vemurafenib
- View vemurafenib alcohol/food interactions (1)
- View vemurafenib disease interactions (7)
Most frequently checked interactions
View interaction reports for vemurafenib and the medicines listed below.
- Abraxane (paclitaxel protein-bound)
- Activated Charcoal (charcoal)
- Adriamycin (doxorubicin)
- Aspirin Low Strength (aspirin)
- Avastin (bevacizumab)
- Casodex (bicalutamide)
- Co-trimoxazole (sulfamethoxazole / trimethoprim)
- Coenzyme Q10 (ubiquinone)
- Colace (docusate)
- Compazine (prochlorperazine)
- Copper (copper gluconate)
- Dextrose (glucose)
- Diltiazem Hydrochloride SR (diltiazem)
- Dulcolax Stool Softener (docusate)
- Fentanyl Transdermal System (fentanyl)
- L-Arginine (arginine)
- L-Carnitine (levocarnitine)
- L-Cysteine (cysteine)
- Lithium Carbonate ER (lithium)
- Lovenox (enoxaparin)
- Metoprolol Succinate ER (metoprolol)
- Metoprolol Tartrate (metoprolol)
- Paracetamol (acetaminophen)
- Valproate Sodium (valproic acid)
- Vitamin B1 (thiamine)
- Vitamin B12 (cyanocobalamin)
- Vitamin B6 (pyridoxine)
- Vitamin D3 (cholecalciferol)
- Vitamin K (phytonadione)
- Vitamin K2 (menaquinone)
Vemurafenib alcohol/food interactions
There is 1 alcohol/food interaction with vemurafenib.
Vemurafenib disease interactions
There are 7 disease interactions with vemurafenib which include:
- lung toxicity
- cutaneous malignancies
- dermatological reactions
- hepatic impairment
- QT prolongation
- renal impairment
- visual complications
Report options
More about vemurafenib
- vemurafenib consumer information
- Compare alternatives
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Zelboraf
Zelboraf (vemurafenib) is used to treat skin cancer (metastatic melanoma). Includes Zelboraf side ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
